The study of antiatherogenic properties of a new combined agent based on the carrot root thick extract and quercetin on the model of experimental atherosclerosis in rabbits

Authors

DOI:

https://doi.org/10.24959/nphj.26.198

Keywords:

quercetin; thick extract of cultivated carrots; antiatherogenic effect.

Abstract

Aim. To study antiatherogenic properties of a new combined agent based on the carrot root thick extract and quercetin on the model of experimental atherosclerosis in rabbits.

Materials and methods. Experimental atherosclerosis was reproduced by oral administration of an oil solution of cholesterol in the dose of 0.3 g/kg to rabbits for 3 months. A combined agent based on the carrot root thick extract and quercetin in the dose of 200 mg/kg and reference drugs simvastatin tablets in the dose of 5 mg/kg, nicotinic acid tablets in the dose of 180 mg/kg, and “Ravisol” tincture (Visci albi сormi et folia; Equiseti arvensis herba; Sophora japonica fructus; Hippocastani semina; Crataegi fructus; Trifolii flores; Vincae minoris hеrbа) in the dose of 360 mg/kg were administered in a therapeutic and prophylactic mode once daily during the reproduction of the pathology for 3 months. The antiatherogenic effect of the agents was assessed by the content of total cholesterol, triglycerides, LDL-C, HDL-C in the blood serum and the atherogenicity coefficient.

Results. It was found that the combined agent based on the carrot root thick extract and quercetin when administered for therapeutic and prophylactic purposes exhibited pronounced antiatherogenic properties, which were indicated by a statistically significant decrease in total cholesterol by 38.3 %, triglycerides by 37.4 %, and LDL-C by 45.7 %, respectively, and, at the same time, an increase in the HDL-C content by 27.6 % and a decrease in the atherogenicity coefficient by 2.9 times compared to the control pathology group. The mechanism of action includes hypolipidemic, hypoglyceridemic, and hypocholesterolemic effects, in which the combined agent does not differ from simvastatin tablets and surpasses nicotinic acid tablets and combined herbal preparation – “Ravisol” tincture.

Conclusions. When rabbits were administered cholesterol for 3 months, significant changes in the lipid spectrum of the blood serum were observed, indicating the development of atherogenic disorders. The combined agent based on the carrot root thick extract and quercetin, with therapeutic and preventive administration against the background of a cholesterol diet shows pronounced antiatherogenic properties at the level of the hypolipidemic agent – simvastatin tablets. The results obtained substantiate the feasibility of further pharmacological studies of a combined agent based on the carrot root thick extract and quercetin as a promising antiatherogenic drug.

References

  1. Xu, S., Kamato, D., Little, P. J., Nakagawa, S., Pelisek, J., & Jin, Z. G. (2019). Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. Pharmacology Therapeutics, 196, 15–43. http://doi.org/10.1016/j.pharmthera.2018.11.003
  2. Thompson, G. R. (2018). Atherosclerosis in cholesterol-fed rabbits and in homozygous and heterozygous LDL receptor-deficient humans. Atherosclerosis, 276, 148–154. http://doi.org/10.1016/j.atherosclerosis.2018.07.032
  3. Fukami, H., & Oike, Y. (2025). ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 32(9), 1071–1078. http://doi.org/10.5551/jat.RV22038
  4. Mihaila, R. G. (2020). Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review. Current Cardiology Reviews, 16(1), 36–47. http://doi.org/10.2174/1573403X15666190522100041
  5. Gianazza, E., Brioschi, M., Martinez Fernandez, A. Casalnuovo, F., Altomare, A., Aldini, G., & Banfi, C. (2021). Lipid Peroxidation in Atherosclerotic Cardiovascular Diseases. Antioxidants Redox Signaling, 34(1), 49–98. http://doi.org/10.1089/ars.2019.7955
  6. German, C. A., & Liao, J. K. (2023). Understanding the molecular mechanisms of statin pleiotropic effects. Archives of Toxicology, 97(6), 1529–1545. http://doi.org/10.1007/s00204-023-03492-6
  7. Yu, D., & Liao, J. K. (2022). Emerging views of statin pleiotropy and cholesterol lowering. Cardiovascular Research, 118(2), 413–423. http://doi.org/10.1093/cvr/cvab032
  8. Chilbert, M. R., VanDuyn, D., Salah, S., Clark, C. M., & Ma, Q. (2022). Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights. Drug Design, Development and Therapy, 16, 2177–2186. http://doi.org/10.2147/DDDT.S332352
  9. Netala, V. R., Teertam, S. K., Li H., & Zhang, Z. A. (2024). Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells, 13(17), 1471. http://doi.org/10.3390/cells13171471
  10. Ruscica, M., Ferri, N., Banach, M., Sirtori, C. R., & Corsini A. (2023). Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovascular Research, 118(17), 3288–3304. http://doi.org/10.1093/cvr/cvac020
  11. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022). The Lancet, 400(10355), 832–845. http://doi.org/10.1016/S0140-6736(22)01545-8
  12. Lagunas-Rangel, F. A., Liepinsh, E., Fredriksson, R., Alsehli, A. M., Williams, M. J., Dambrova, M., Jönsson, J., & Schiöth, H. B. (2024). Off-target effects of statins: molecular mechanisms, side effects and the emerging role of kinases. British Journal of Pharmacology, 181(20), 3799–3818. http://doi.org/10.1111/bph.17309
  13. Cheon, D. Y., & Jo, S.-H. (2022). Adverse effects of statin therapy and their treatment. Cardiovascular Prevention and Pharmacotherapy, 4(1), 1–6. http://doi.org/10.36011/cpp.2022.4.e4
  14. Melguizo-Rodriguez, L., Garcia-Recio, E., Ruiz, C., De Luna-Bertos, E., Illescas-Montes, R., & Costela-Ruiz, V. J. (2022). Biological properties and therapeutic applications of garlic and its components. Food Function, 13, 2415–2426. http://doi.org/ 10.1039/D1FO03180E
  15. Wang, L., Zheng, W., Yang, J., Ali A., & Qin, H. (2022). Mechanism of Astragalus membranaceus alleviating acquired hyperlipidemia induced by high-fat diet through regulating lipid metabolism. Nutrients, 14(5), 954. http://doi.org/10.3390/nu14050954
  16. Rahmani, J., Manzari, N., Thompson, J., Clark, C. C. T., Villanueva, G., Varkaneh, H. K., & Mirmiran, P. (2019). The effect of saffron on weight and lipid profile: a systematic review, meta-analysis and dose–response of randomized clinical trials. Phytotherapy Research, 33(9), 2244–2255. http://doi.org/10.1002/ptr.6420
  17. Zheng, X. X., Xu, Y. L., Li, S. H., Liu, X. X., Hui, R., & Huang, X. H. (2011). Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. The American Journal of Clinical Nutrition, 94(2), 601–610. http://doi.org/10.3945/ajcn.110.010926
  18. Hussain, S. A., Aziz, T. A., Mahwi, T. O., & Ahmed, Z. A. (2022). Gingko biloba extract improves the lipid profile, inflammatory markers, leptin level and the antioxidant status of T2DM patients poorly responding to metformin: a double-blind, randomized, placebo-controlled clinical trial. Brazilian Journal of Pharmaceutical Sciences, 58, e19516. http://doi.org/10.1590/S2175-97902022e19516
  19. Panahi, Y., Khalili, N., Sahebi, E., Namazi, S., Reiner, Z., Majeed, M., & Sahebkar, A. (2017). Curcuminoids modify lipid profile in type 2 diabetes mellitus: a randomized controlled trial. Complementary Therapies in Medicine, 33, 1–5. http://doi.org/10.1016/j.ctim.2017.05.006
  20. Netala, V. R., Teertam, S. K., Li, H., & Zhang, Z. (2024). Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells, 13(17), 1471. http://doi.org/10.3390/cells13171471
  21. Parvin, A., Yaghmaei, P., Noureddini, M., Haeri Roohani, S. A., & Aminzadeh, S. (2019). Comparative effects of quercetin and hydroalcoholic extract of Otostegia persica boiss with atorvastatin on atherosclerosis complication in male wistar rats. Food Science Nutrition, 7(9), 2875–2887. http://doi.org/10.1002/fsn3.1136
  22. Alizadeh, S. R., & Ebrahimzadeh, M. A. (2022). Quercetin derivatives: Drug design, development, and biological activities, a review. European Journal of Medicinal Chemistry, 229, 114068. http://doi.org/10.1016/j.ejmech.2021.114068
  23. Yang, G., Han, D., Ma, J., & Zhang, X. (2019). Efficacy of Ezetimibe/Simvastatin (10/10 mg) versus High Dose Statin in Dyslipidemia Patients: A Meta-Analysis of Randomized Controlled Trials. Iranian Journal of Public Health, 48(8), 1405–1417.
  24. Lyseng-Williamson, K. A. (2010). Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation. Drugs in R&D, 10(4), 253–260. http://doi.org/10.2165/11202560-000000000-00000
  25. Farmatsevtychna likuvalno-profilaktychna kompozytsiia na osnovi roslynnoi syrovyny (2009). (Patent Ukrainy № u 200903174).
  26. Stefanov, O. V. (Red.). (2001). Doklinichni doslidzhennia likarskykh zasobiv: metod. rek. Avitsena.
  27. Lutsyk, B. D., Lapovets, L. Ye., Lebed, H. B., Akimova, V. M., & Mishunin, I. F. (2018). Klinichna laboratorna diahnostyka: navch.posib. dlia VNZ III-IV r. a. (2-he vyd.). Medytsyna.
  28. Koike, T., Koike, Y., Yang, D., Guo, Y., Rom, O., Song, J., Xu, J., Chen, Y., Wang, Y., Zhu, T., Garcia-Barrio, M. T., Fan, J., Eugene Chen, Y., & Zhang, J. (2021). Human apolipoprotein A-II reduces atherosclerosis in knock-in rabbits. Atherosclerosis, 316, 32–40. http://doi.org/10.1016/j.atherosclerosis.2020.11.028
  29. Kononenko, T. R., & Chikitkina, V. V. (2024). Doslidzhennia antyaterohennoi dii kombinovanoho zasobu na osnovi morkvy posivnoi koreneplodiv ekstraktu hustoho ta kvertsetynu na modeli kholesterynovoho ateroarteriosklerozu v kroliv. Health Education, (3), 70–80.
  30. Jia, Q., Cao, H., Shen, D., Li, S., Yan, L., Chen, C., Xing, S., & Dou, F. (2019). Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1. International Journal of Molecular Medicine, 44(3), 893–902. http://doi.org/10.3892/ijmm.2019.4263
  31. Shakheel, M. B., Saliyan, T., Satish, S., & Hedge, K. (2017). Therapeutic Uses of Daucus carota: A Review. International Journal of Pharma And Chemical Research, 3(2), 138–143.
  32. Julius, U. (2015). Niacin as antidyslipidemic drug. Canadian Journal of Physiology and Pharmacology, 93(12), 1043–1054. http://doi.org/10.1139/cjpp-2014-0478

Downloads

Published

2026-03-31

Issue

Vol. 111 No. 1 (2026): News of Pharmacy

Section

Articles

License

Copyright (c) 2026 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.